Document:

<PAGE>

                                                                    Exhibit 10.6

          CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
         SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                 FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

     This First Amendment (this "Amendment") to the Exclusive License Agreement
(the "License Agreement"), dated as of January 29, 2007, by and between Critical
Therapeutics, Inc., a Delaware corporation ("Licensor"), and Innovative
Metabolics, Inc., a Delaware corporation ("IMI"), is entered into on June 29,
2007 by and between the Licensor and IMI. Any capitalized terms used, but not
defined, herein shall have the meanings ascribed to them in the License
Agreement.

     WHEREAS, pursuant to the License Agreement, Licensor granted an exclusive
license to IMI under the Licensed Patents and Licensed Know-How for IMI to
research, develop and commercialize the Licensed Products & Methods.

     WHEREAS, Exhibit C of the License Agreement allows for IMI to support
Sponsored Research in the Field.

     WHEREAS, IMI desires to support certain Sponsored Research and Licensor is
willing to have such Sponsored Research conducted under the NS License.

     WHEREAS, since the effective date of the License Agreement, Provisional
Patent Application, No. [**] has been filed with the United States Patent and
Trademark Office.

     WHEREAS, Kevin J. Tracey, M.D. has assigned his right, title and interest
to the Stimulation Technology to NS, and Dr. Shaw Warren, Jr., M.D. has assigned
his right, title and interest to the Stimulation Technology to Licensor.

     WHEREAS, pursuant to the NS License, Licensor has certain rights to NS's
interest in the Stimulation Technology and Licensor desires to sublicense those
rights to IMI under the License Agreement.

     WHEREAS, Licensor and IMI desire to clarify certain patent prosecution
matters related to certain of the NS Licensed Patents.

     NOW, THEREFORE, acting in accordance with Section 10.4 of the License
Agreement, the Parties hereby agree as follows:

Section 1. Sponsored Research.

     The Parties hereby agree that Licensor shall have NS perform the research
outlined on Exhibit A hereto (the "Additional Research") as Sponsored Research
under the NS License during calendar year 2007. On or before July 16, 2007, IMI
shall pay Licensor for the Additional Research in accordance with the budget set
forth on Exhibit A hereto, and Licensor shall forward all appropriate monies to
NS. The Parties hereby further agree that the activities and results of the
Additional Research shall be treated as "North Shore Patent Rights" or "North
Shore Technology", as appropriate, under the NS License and that any North Shore
Patent Rights arising from the Additional Research shall be treated as "Field
Only Licensed Patent Rights" under the License Agreement and that any North
Shore Technology arising from the Additional Research shall be treated as "NS
Licensed Know-How" under the License Agreement.

Section 2. Patent Prosecution.

     2.1 Licensor hereby acknowledges and agrees that the Stimulation Technology
is jointly owned by Licensor and NS. The Parties hereby agree that NS's interest
in the Stimulation Technology shall be treated as "Field Only Licensed Patent
Rights" for all purposes under the License Agreement (including Royalties
payable pursuant to Section 5.3 thereof).

     2.2 The Parties hereby amend Exhibit A of the License Agreement as follows:
the words "None as of the Effective Date" are hereby deleted and replaced with
"Based on the Assignment from H. Shaw Warren, Jr., M.D. to Licensor, Licensor's
joint interest in U.S. Application No. [**]

<PAGE>

     2.3 The Parties hereby amend Exhibit B of the License Agreement by adding
the following row to the end of the table in Exhibit B:

<TABLE>
<S>    <C>    <C>    <C>    <C>    <C>
[**]   [**]   [**]   [**]   [**]   [**]
</TABLE>

     2.4 Licensor and IMI hereby agree that as of June 16, 2007, the following
patent applications shall be prosecuted and maintained by IMI in accordance with
the terms of Section 6.1(b)(ii) of the License Agreement:

<TABLE>
<CAPTION>
         APP. NO./     COUNTRY/     PARENT/     PATENT NO. (IF
TITLE   FILING DATE   FILE TYPE   FILING DATE     APPLICABLE)    CRTX DOCKET NO.
-----   -----------   ---------   -----------   --------------   ---------------
<S>     <C>           <C>         <C>           <C>              <C>
[**]       [**]          [**]         [**]            [**]             [**]
[**]       [**]          [**]         [**]            [**]             [**]
[**]       [**]          [**]         [**]            [**]             [**]
</TABLE>

Notwithstanding the foregoing, the Parties agree that at any time, at Licensor's
reasonable request, on a country-by-country basis, IMI shall file a divisional,
continuation, continuation-in-part or other like patent application claiming
priority to any of the [**] patent applications listed in the immediately
preceding table for Licensor to prosecute and maintain; provided that within
[**] days of receipt of invoices from IMI, Licensor shall pay [**] percent
([**]%) of the costs incurred by IMI to prosecute and maintain the patent that
is the subject of Licensor's request from June 16, 2007 through the date of the
request and all times thereafter.

Section 3. General Provisions.

     3.1 Applicable Law. This Amendment shall be governed by and construed in
accordance with the laws of The Commonwealth of Massachusetts, without regard to
its conflicts of law provisions, provided that any dispute relating to the
scope, validity, enforceability or infringement of any Patent Rights or other
intellectual property rights shall be governed by, and construed and enforced in
accordance with, the substantive laws of the jurisdiction in which such Patent
Rights or other right applies.

     3.2 Effect on License Agreement; Entire Agreement. Except as otherwise
expressly provided herein, the License Agreement shall remain in full force and
effect. This Amendment (including the Exhibit attached hereto), together with
the License Agreement, contains the entire understanding of the Parties with
respect to the subject matter hereof and supersedes and replaces any and all
previous arrangements and understandings other than the CDA, whether oral or
written, between the Parties with respect to the subject matter hereof.

                [Remainder of this Page Intentionally Left Blank]

                                        2

<PAGE>

     IN WITNESS WHEREOF, the Parties have caused this First Amendment to the
Exclusive License Agreement to be executed by their respective duly authorized
officers as of the Effective Date.

                                        INNOVATIVE METABOLICS, INC.

                                        By: /s/ James W. Broderick
                                            ------------------------------------
                                            (Signature)
                                        Name: James W. Broderick, M.D.
                                        Title: Chief Executive Officer

                                        CRITICAL THERAPEUTICS, INC.

                                        By: /s/ Trevor Phillips
                                            ------------------------------------
                                            (Signature)
                                        Name: Trevor Phillips, Ph.D.
                                        Title: Chief Operating Officer

<PAGE>

                                    EXHIBIT A

                            RESEARCH PLAN AND BUDGET

[**]

<TABLE>
<CAPTION>
        Category            Detail   Amount
        --------            ------   ------
<S>                         <C>      <C>
[**] Subjects                [**]     $[**]
Data Entry and management    [**]     $[**]
Overhead                     [**]     $[**]
                                      -----
Total                                 $[**]
                                      =====
</TABLE><PAGE>

                                                                    Exhibit 10.7

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisk denote omissions.

                           AMENDMENT NO. 3 RELATING TO
                    SPONSORED RESEARCH AND LICENSE AGREEMENT
                                     BETWEEN
                           CRITICAL THERAPEUTICS, INC.
                                       AND
                  THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
                              DATED JANUARY 1, 2003

THIS AMENDMENT NO. 3 is made the 29th day of June, 2007.

BETWEEN:

(1)  CRITICAL THERAPEUTICS, INC., a Delaware corporation ("CTI"); and

(2)  THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH, a New York not-for-profit
     corporation ("FEINSTEIN")

RECITALS:

     (A)  CTI and Feinstein entered into a Sponsored Research and License
          Agreement, dated January 1, 2003.

     (B)  The said Sponsored Research and License Agreement was modified by that
          certain Letter Agreement between CTI and Feinstein dated February 3,
          2004, and was amended by each of Amendment No. 1 dated September 18,
          2006 and Amendment No. 2 dated January 8, 2007. The Sponsored Research
          and License Agreement as so modified and so amended is referred to
          herein as the "ORIGINAL AGREEMENT".

     (C)  CTI and Feinstein have agreed to amend the Original Agreement by and
          upon the terms of this Amendment No. 3.

OPERATIVE PROVISIONS:

1.   INTRODUCTION, DEFINITIONS AND INTERPRETATION

1.1. This Amendment No. 3 is supplemental to the Original Agreement.

1.2. In this Amendment, the expression "THIS AMENDMENT NO. 3" shall mean this
     Amendment No. 3, including its recitals and schedules.

1.3  Except where expressly provided to the contrary in this Amendment No. 3:

     1.3.1 all capitalized terms used in this Amendment No. 3 shall have the
          same meanings as are assigned thereto in the Original Agreement, as
          amended by this Amendment No. 3; and

<PAGE>

     1.3.2 this Amendment No. 3 shall be interpreted in the same manner as the
          Original Agreement.

1.4  References to clauses and Articles herein are to clauses and Articles of
     the Original Agreement.

2.   AMENDMENTS

NOW THEREFORE, in consideration of the mutual covenants contained in the
Original Agreement and in this Amendment No. 3 and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the
parties agree that with effect from the Amendment No. 3 Date (as defined below),
the Original Agreement is hereby amended as follows:

2.1  Article 1 shall be amended by insertion of the following additional
     definition after Article 1.2(c).:

     "1.2(d). "AMENDMENT NO. 3 DATE" shall mean June 29, 2007."

2.2  ATTACHMENT A shall be amended by adding the following additional Research
     Plan after the Research Plan for the CAP Program:

[**]

<TABLE>
<CAPTION>
        Category            Detail   Amount
        --------            ------   ------
<S>                         <C>      <C>
[**] Subjects                [**]     $[**]
Data Entry and management    [**]     $[**]
Overhead                     [**]     $[**]
                                      -----
Total                                 $[**]
                                      =====
</TABLE>
"

2.3  Section 2.1 shall be amended by adding the following at the end of the
     section:

"In addition to the foregoing amounts, CTI shall pay Feinstein $[**] to conduct
the research regarding [**] set forth in the Research Plan. Feinstein shall
invoice CTI on or after July 16, 2007. CTI shall make payment by check or wire
transfer to Feinstein for such invoiced amount within one (1) month of the date
of CTI's receipt of any invoice issued by Feinstein pursuant to the immediately
preceding sentence."

Schedule 1.7 shall be amended by adding the following at the end of the table:

[**]  [**]   [**]   [**]   [**]   [**]   [**]

[**]

3. NO OTHER AMENDMENTS; CONFIRMATION

<PAGE>

Save as amended by this Amendment No. 3, the parties hereto confirm that the
Original Agreement shall continue in full force and effect in all respects.

4. COUNTERPARTS

This Amendment No. 3 may be signed in any number of counterparts with the same
effect as if the signatures to each counterpart were upon a single instrument,
and all such counterparts together shall be deemed an original of this Amendment
No. 3.

5. GOVERNING LAW AND JURISDICTION

This Amendment No. 3 shall be governed by and construed in accordance with the
laws of the State of New York without regard to any conflict of laws provisions
thereof.

<PAGE>

IN WITNESS whereof the parties have executed and delivered this Amendment No. 3
as of the date first written above.

CRITICAL THERAPEUTICS, INC.

By: /s/ Trevor Phillips
    ----------------------------------
Name: Trevor Phillips, Ph.D.
Title: Chief Operating Officer

THE FEINSTEIN INSTITUTE FOR MEDICAL
RESEARCH

By: /s/ Kirk R. Manogue
    ----------------------------------
Name: Kirk R. Manogue, PhD
Title: Vice President, Technology
       Transfer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}]]